Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,204 across all filing types
Latest filing 2019-07-26 Regulatory Filings
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the intimation of a Board Meeting scheduled to approve unaudited financial results for the quarter ended June 30, 2019. It includes reference to compliance with SEBI regulations and encloses newspaper advertisements about the Board Meeting. The document is short (1579 characters) and does not contain any actual financial data or detailed financial statements. It is an announcement related to a Board Meeting and financial results but does not include the results themselves or detailed management discussion. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a compliance announcement and notification rather than a full interim report or earnings release.
2019-07-26 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification about an upcoming earnings call to discuss the un-audited financial results for the quarter ended June 30, 2019. It provides details about the date, time, and dial-in information for the call, but does not contain the actual financial results or a transcript of the call. The document is short (1958 characters) and serves as an announcement rather than the full transcript or financial report. According to the classification rules, announcements of earnings calls or notifications about them are best classified as Call Transcript (CT) only if the full transcript is included. Since this is only an announcement of the call, it does not fit CT. It is not an earnings release (ER) because it does not contain financial highlights. It is not a report publication announcement (RPA) because it does not mention a report being published or attached. The best fit is Regulatory Filings (RNS) as a general regulatory announcement about the earnings call event.
2019-07-26 English
Board Meeting — Financial Results/Dividend
Board/Management Information Classification · 95% confidence The document is a short announcement dated July 23, 2019, informing stock exchanges about a scheduled Board Meeting on July 29, 2019. The agenda includes approval of unaudited financial results for the quarter ended June 30, 2019, and declaration of an interim dividend. It also mentions the closure of the trading window for insider trading compliance. The document does not contain actual financial data or detailed reports but is a notification of an upcoming board meeting and related agenda items. According to the rules, such announcements about board meetings and agenda fall under Board/Management Information (MANG). The document length is short and it is not a report itself, so it is not an Interim Report or Earnings Release. Therefore, the correct classification is MANG with high confidence.
2019-07-23 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a short announcement informing stock exchanges about the receipt of an Establishment Inspection Report (EIR) from the USFDA confirming the successful closure of an inspection at a manufacturing facility. It is dated July 23, 2019, and addressed to BSE Limited and the National Stock Exchange of India Limited. The content is brief (1243 characters) and does not contain any financial data, detailed report, or analysis. It is an official notification to take the information on record. According to the rules, such short announcements that inform about regulatory or inspection outcomes without detailed financial or operational data fall under Regulatory Filings (RNS).
2019-07-23 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the successful completion of a US FDA inspection at the company's flagship facility. It is a short communication (3338 characters) and does not contain detailed financial data, regulatory certifications, or comprehensive report content. It is not an annual or interim report, audit report, or earnings release. It is an announcement of an event related to regulatory inspection results. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into more specific categories like earnings, management changes, or capital updates.
2019-07-20 English
News Verification
Regulatory Filings Classification · 95% confidence The document is a letter from Strides Pharma Science Limited addressing a clarification regarding a news article about a US FDA warning letter received by the company. It references prior disclosure made under Regulation 30 of SEBI LODR about the warning letter and its impact on operations. The content is a regulatory announcement clarifying a specific event and referencing prior filings. The document length is 3335 characters, which is relatively short and does not contain financial statements or detailed financial data. It is not an annual or interim report, earnings release, or any detailed financial or management report. It is a regulatory disclosure/clarification letter related to compliance and regulatory matters. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-07-17 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.